• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech initiates the collaboration with Healthcare Global Enterprises Ltd (HCG)

Scandinavian ChemoTech initiates the collaboration with Healthcare Global Enterprises Ltd (HCG)

Report this content

After a successful training and certification of doctors and nurses at HCG Cancer Centre in Bengaluru in India, the team treated its first patient after the lifting of the COVID-19 lockdown.

In March 2020 ChemoTech and HCG engaged in an agreement to perform a scientific evaluation of IQwave and the TSE (Tumour Specific Electroporation™). The evaluation is led by HCGs Department of Translational Medicine.

After the training and certification of doctors and nurses, that took place in early November at HCG’s state of the art cancer centre in Bengaluru India, this important collaboration could finally begin.

“Even if the COVID–19 situation is far from over we are very happy that this program was able to take off. This evaluation is the first step in a larger launch within the HCG group. It is therefore of great importance to both us and the HCG team.” - says Mohan Frick CEO

“Despite the risks posed by COVID-19, we are happy that our oncology team has been trained and designated a certified centre for the TSE therapy. Our plan is now to accelerate the evaluation program and the collaboration with ChemoTech. Last week we treated the first patient since the COVID-19 lockdown.” - says Dr. Suhail Sayeed Mufti, Director at the Department of Translational Medicine & Therapeutics HCG

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00



Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se